We also found a strong linear correlation between GZMK and PD-1 in breast cancer, providing a new therapeutic target for further exploration of breast cancer immunotherapy, especially in triple-negative breast cancer. This evidence concerns the gene GZMK and triple-negative breast carcinoma.